Treatment and Prognosis of Systemic Lupus Erythematosus
There are many different pharmacologic options for treatment/management of Systemic Lupus Erythematosus (SLE). While there is no cure for this autoimmune disease, the goal is to control the progression of the disease through pharmaceutical therapies. Combination therapy may also be appropriate. It is essential to develop a unique, individualized plan with your Rheumatologist so that the appropriate intervention be utilized based on disease location and severity. Pharmacotherapy includes classes of drugs such as Antimalarials, Corticosteroids, Non-biologic DMARDS, biologic DMARDS, and NSAIDS. All of these medications have side effects, and the risks versus the benefits should be weighed before any intervention. Antimalarial medications such as Plaquenil have been used to control the progression of SLE. Corticosteroids, commonly used in Prednisone, are added to treatment plans to decrease the inflammation associated with Lupus. Non-biologic DMARDS, such as Methotrexate, and biologic DMARDS, such as rituximab, are also used to stabilize the condition. There is a specific protocol that must be followed for treatment of SLE. It is imperative that a unique treatment plan is developed for your individual stage of SLE. Combination therapy may be suggested. Some of the medications may be short term and others may be long term therapy. It can be a tedious process to determine the most appropriate therapy that will allow for best symptom control and delayed disease progression.